A share price of Dynavax Technologies Corp. [DVAX] is currently trading at $13.14, up 3.06%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DVAX shares have gain 5.88% over the last week, with a monthly amount drifted -4.44%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance. In a post published today on Yahoo Finance, HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million.
From an analyst’s perspective:
Dynavax Technologies Corp. [NASDAQ: DVAX] stock has seen the most recent analyst activity on February 01, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $20. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 27, 2022, and set its price target to $22. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $19 on August 06, 2021. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $12 on August 07, 2020. H.C. Wainwright reiterated a Buy rating for this stock on August 03, 2020, and upped its price target to $14. In a note dated June 15, 2020, Evercore ISI initiated an Outperform rating and provided a target price of $14 on this stock.
Dynavax Technologies Corp. experienced fluctuations in its stock price throughout the past year between $9.42 and $15.15. Dynavax Technologies Corp. [NASDAQ: DVAX] shares were valued at $13.14 at the most recent close of the market.
Analyzing the DVAX fundamentals
Trailing Twelve Months sales for Dynavax Technologies Corp. [NASDAQ:DVAX] were 361.18M which represents -58.56% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.79 points at the first support level, and at 12.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.35, and for the 2nd resistance point, it is at 13.55.
Dynavax Technologies Corp. [DVAX] reported earnings per share of $0 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.01/share, meaning a difference of $0.01 and a surprise factor of 100.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.1 per share as compared to estimates of -$0.01 per share, a difference of $0.11 representing a surprise of 1,100.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dynavax Technologies Corp. [NASDAQ:DVAX] is 15.40. In addition, the Quick Ratio stands at 14.49 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 4.75, the price to book ratio is 2.81 and price to earnings (TTM) ratio is 34.23.
Transactions by insiders
Recent insider trading involved Janssen Robert, SVP and CMO, that happened on Jan 04 when 1500.0 shares were sold. President & COO, Novack David F completed a deal on Jan 02 to sell 9000.0 shares. Meanwhile, President & COO Novack David F sold 20000.0 shares on Dec 01.
